Clifford R. Jack Jr., M.D. is Professor of Radiology and the Alexander Family Professor of Alzheimer’s Disease Research at Mayo Clinic in Rochester MN. His research group is engaged in brain imaging research in cognitive aging and Alzheimer's disease and related disorders. Specific goals are to understand how various imaging measures relate to neuropathology, fluid biomarkers, genetics, psychometric, and cognitive/ behavioral phenotypes. All modern brain imaging modalities are used including amyloid PET, FDG PET, tau PET, anatomic MRI, diffusion imaging, perfusion imaging, task free functional MRI, and quantitative susceptibility mapping. The group also serves as the MR center for large multi-site observational and interventional studies including ADNI, DIAN, the ACTC consortium (e.g. A4, AHEAD 3-45), ARIC, Jackson Heart Study and SCAN.

My main focus of study is looking at the effect of APOE on the brain in both health and disease and trying to find ways to prevent the negative effects of ApoE4 while promoting the positive effects of ApoE2.

Sam Jackson, MD, is the Chief Medical Officer of Neuron23, a company combining cutting-edge data science and human genetics to create precision therapeutics for debilitating diseases.

Dr. William Jagust is a Professor of Public Health and Neuroscience at the University of California, Berkeley, and a Faculty Senior Scientist at Lawrence Berkeley National Laboratory. Prior to that appointment he was the Chair of the Department of Neurology at the University of California, Davis and founding director of the UC Davis Alzheimer’s Disease Center. Dr. Jagust’s career has been focused on understanding the aging brain, and particularly the borderland between normal cognitive aging and Alzheimer’s disease. His laboratory has pioneered in the use of multimodal imaging to understand brain aging and Alzheimer’s disease, employing positron emission tomography (PET) to measure -amyloid and tau proteins in the brain, and magnetic resonance imaging (MRI) to investigate how these protein aggregates affect neural function and structure. He has served on editorial boards of major journals, advisory boards to the National Institute on Aging. His laboratory leads the PET component of numerous multicenter studies including the Alzheimer’s Disease Neuroimaging Initiative, the POINTER imaging study, SCAN, and the HEAD project. He is a recipient of the 2013 Potamkin Prize for Research in Pick’s, Alzheimer’s and Related Diseases.

Julia Jahansooz graduated from the University of California, Berkeley with a degree in Integrative Biology. She went on to earn her master’s degree in Clinical and Translational Research from the University of Hawai’i and is now a second year medical student at the John A. Burns School of Medicine. Julia believes research is the backbone of clinical practice and encourages everyone to participate in some level of research during their career.

Hieronim Jakubowski obtained his MSc degree in physical chemistry from the Adam Mickiewicz University Poznań (1969), PhD degree in biochemistry from the Agricultural University, Poznań (1974), and Dr. habil. degree (habilitation) in biochemistry from the Institute of Biochemistry and Biophysics, Warsaw (1978). He was a Postdoctoral Fellow at the University of New Mexico, Albuquerque, NM, USA (1975 - 1976) and a FEBS Fellow at the Hanover Medical School, Germany (Apr - Jul 1982). He was an EMBO Fellow at the Imperial College of Science and Technology, London, UK (Nov - Dec 1980), where he discovered biological synthesis of the thioester homocysteine thiolactone during homocysteine editing by aminoacyl-tRNA synthetases. He took a Yeast Genetics and Molecular Biology Course at the Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA (Jul - Aug 1987). He received a title of Professor from the President of Poland (Dec 2007). He has made seminal discoveries in the field of tRNA synthetases and error-editing mechanisms in protein biosynthesis, which provided foundation for his more recent discoveries of mechanisms involved in the incorporation of homocysteine into protein, as well as his studies of homocysteine-containing proteins and their role in cardiovascular and neurodegenerative diseases. He is currently an Adjunct Professor of Microbiology, Biochemistry and Molecular Genetics at Rutgers University, New Jersey Medical School, Newark, NJ, USA and a Professor at the Department of Biochemistry and Biotechnology, University of Life Sciences, Poznań, Poland.

Alberto Jaramillo-Jimenez (Medellín, Colombia) received his Medical Doctor degree at the University of Antioquia, Colombia in 2019. As an undergraduate student, he was trained in EEG with the Group of Neuroscience of Antioquia, assessing participants from the largest worldwide cohort with Early-Onset Autosomal Dominant Alzheimer's Disease due to PSEN1 - E280A. In 2020 he started his Ph.D. in Health and Medicine at the University of Stavanger, Norway. His current work at the Centre for Age-Related Medicine (SESAM) is focused on the sensor-level analysis of multiple EEG features for the classification of multiple diseases leading to neurodegeneration. Currently, he is a member of the Global Brain Consortium (Dementia Biomarkers group), as well as part of the European Consortium of Dementia with Lewy Bodies (EEG Hub).

Karolina Jarawka is a partnering lead in neurology at Roche Diagnostics. Her focus is on exploring new areas of collaborative opportunities across pharma, biotech, philanthropy and academia stakeholders. She joined Roche Diagnostics in 2012 and in the first 7 years she was driving portfolio management activities as well as led multiple strategic initiatives. Prior to this she had worked at Bayer Material Science in Germany in Mergers & Acquisitions where she gained extensive experience in all aspects of deal management and in Post Merger Integration. Karolina holds a Business Master in International Finance from the University of Economics and Business in Poznan, Poland and a Business Master in International Management from the University of Paderborn, Germany.

Javier Jarazo is co-founder and CSO of OrganoTherapeutics (OT) a spin-off of the University of Luxembourg. During his PhD at the Luxembourg Centre for Systems Biomedicine, he developed in vitro models (mainly organoids) for identifying novel modifiers of Parkinson’s disease (PD), as well as establishing a high content high throughput pipeline for screening compounds, using an automated platform. Now in his role of CSO, he guides the focus of OT in drug discovery and disease model development, enabling personalized and precision medicine in PD.

PhD student at the Divison of Pathology, currently writing a thesis on risk factors for Alzheimer's disease and Lewy body disease with a specific focus on cardiovascular disease, hypertension, and type 2 diabetes mellitus. Additionally, the project intends to explore the presence of cardiac alpha-synuclein and its role in the cause of death in alpha-synucleinopathies.